Drugs / TLC388
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00747474 | Sep 2008 → Aug 2011 | — | Taiwan Liposome Company | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03035006 | Apr 2017 → Oct 2018 | hepatocellular carcinoma, portal vein thrombosis | Taiwan Liposome Company | Terminated | No outcome recorded |
| Phase 1/2 | NCT01425996 | Oct 2011 → Oct 2014 | hepatocellular carcinoma | Taiwan Liposome Company | Terminated | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT02457273 | Jul 2015 → Apr 2018 | neuroendocrine carcinoma | National Health Research Institutes, Taiwan | Completed | No outcome recorded |
| Phase 2 | NCT02267213 | Apr 2014 → Jul 2015 | hepatocellular carcinoma | Taiwan Liposome Company | Terminated | No outcome recorded |
| Phase 2 | NCT01831973 | Nov 2012 → Mar 2015 | renal cell carcinoma | Taiwan Liposome Company | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TLC388 | “The purpose of this study is to evaluate the safety and efficacy of TLC388 (Lipotecan) as a second line treatment in subjects with advanced Hepatocellular Carcinoma.” NCT02267213 ↗3“This study analyzed the efficacy of TLC388 (Lipotecan) Hydrochloride, a novel camptothecin analog, for pretreated patients with metastatic NEC.” PMID 31852810 ↗ Dec 2019 |
| Known as | Lipotecan | “Lipotecan® is a drug product of TLC388 HCl, which is a potent camptothecin analog with cytotoxic activities against a variety of human tumor cell lines and anti-tumor...” NCT01425996 ↗ |
| Known as | Lipotecan (TLC388) | “Lipotecan (TLC388)” NCT00747474 ↗ |
| Known as | Lipothecan free base | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594352 ↗ |
| Known as | TLC388 HCl | “Lipotecan® is a drug product of TLC388 HCl, which is a potent camptothecin analog with cytotoxic activities against a variety of human tumor cell lines and anti-tumor...” NCT01425996 ↗ |
| Action | Inhibit | “DNA topoisomerase I inhibitor” CHEMBL4594352 ↗1“a Topoisomerase I inhibitor” NCT02457273 ↗ |
| Modality | Small molecule | “a novel camptothecin analog” PMID 31852810 ↗ Dec 2019 |
| Route | Intravenous | “Lipotecan IV day 1, 8, 15” NCT00747474 ↗ |
| Target | TOP1 | “DNA topoisomerase I inhibitor” CHEMBL4594352 ↗ |